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Abstract 
 Doxorubicin, a widely used chemotherapeutic agent, generates free radicals which may 
increase lipid peroxidation and oxidative stress. Research suggests that sucrose increases oxidative 
stress; conversely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) limit oxidative 
stress and lipid peroxidation in the brain of mice treated with doxorubicin. It is unknown how the 
combination of sucrose and omega-3 fatty acids impacts lipid peroxidation in metabolically 
important tissues such as the liver in the presence of chemotherapy or mammary tumors. Livers 
from mouse models of breast cancer (Tumor model: n=32; 8/diet) and chemotherapy (Chemo 
model: n=40;10/diet) were analyzed for 4-hydroxynonenal (4-HNE), a lipid peroxidation marker, 
using an enzyme-linked immunoabsorbent assay. In both experiments, 8-9 week old female 
C57BL/6 mice were ovariectomized and randomized to diets one week later. Tumor model mice 
were fed low sucrose diets, with either 0% or 2% kcal from EPA+DHA. Two weeks later, mice 
were injected with metastatic mammary tumor cells or control; after 21 days, tissues were collected. 
Chemo model mice were fed low sucrose, 0% or 2% kcal EPA+DHA diets, or high sucrose, 0% 
or 2% kcal EPA+DHA diets. Mice were injected with doxorubicin based chemotherapy or saline 
two and four weeks later; tissues were collected 11 days after second injection. Mean liver 4-HNE 
in tumor mice (0.0649ug HNE-BSA/ugProtein; SEM 0.0066) vs. control (0.0613ug HNE-
BSA/ugProtein; SEM 0.0066) was not significantly different (p=0.71) and did not differ by diet 
(p=0.54). Similarly, mean liver 4-HNE in chemo mice (0.0817ug HNE-BSA/ugProtein; SEM 
0.0114) vs. control (0.0877ug HNE-BSA/ugProtein; SEM 0.0117) was not significantly different 
(p=0.72) and did not differ by diet (p=0.42). In conclusion, we found no differences in liver lipid 
peroxidation in chemotherapy-treated or tumor mice vs. controls when fed varying levels of 
sucrose and EPA+DHA.  
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Introduction 
 In the United States of America (US), breast cancer is the second leading cause of death in 
women6. Doxorubicin and cyclophosphamide are widely used as antitumor drugs for treatment of 
cancer, in particular breast cancer10,15. But, an exposure to doxorubicin through chemotherapy 
could mediate generation of free radicals in the brain tissues as it promotes lipid peroxidation 
which changes the antioxidant defense system and may lead to neuropsychological changes in 
mice model15. Doxorubicin’s anticancer action is believed to be caused by free radical generation 
through redox reaction which causes DNA damage, however the mechanism of free radical 
formation by doxorubicin remains unknown9. Also, the usage of cyclophosphamide kills immune 
cells in the body through selective suppression of regulatory T cells and that affects the therapeutic 
efficacy of chemotherapy10. In a recent review regarding rodents’ brains, it was mentioned that the 
addition of omega-3 fatty acids especially EPA and DHA in the diet has been known for reducing 
oxidative stress in the brains of male rats12. In contrast, high levels of dietary sucrose were 
associated with increasing lipid peroxidation in brain of mouse models as well as counteracting 
the anti-inflammatory effect of the omega-3 fatty acids1,8. 4-hydroxynonenal (4-HNE) is one of 
the end-products and biomarkers of lipid peroxidation and readily generated in brain and liver of 
mice in response to presence of toxicants like doxorubicin16. However, lipid peroxidation after 
feeding a range of sucrose and omega-3 fatty acids at levels typically consumed by women 
undergoing chemotherapy for breast cancer have yet to be studied. Additionally, it is still not 
known how the combination of sucrose and omega-3 fatty acids impact lipid peroxidation in the 
liver when chemotherapy is administered. It is important to look at liver’s response to the 
chemotherapy treatment and varying levels of sucrose and omega-3 fatty acids because it is a major 
organ responsible for detoxification of drugs as well as synthetic function of many biochemical 
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pathways13. This study was aimed to investigate the effects of sucrose and omega-3 dietary 
modification on lipid peroxidation in the liver of mouse models of breast cancer and chemotherapy. 
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Literature review 
In this literature review, relevant studies are grouped into three categories: effects of 
mammary tumor and omega-3 fatty acids on lipid peroxidation in the liver; effects of 
chemotherapy and omega-3 fatty acids on lipid peroxidation in the liver; effects of omega-3 fatty 
acids and sucrose on lipid peroxidation in the liver.  
Mammary tumors, omega-3 fatty acids and lipid peroxidation in the liver 
There have been very few studies that were designed to examine the relationship between 
mammary tumor, omega-3 fatty acids and lipid peroxidation. Also, they did not measure lipid 
peroxidation via 4-HNE but instead with phospholipid hydroperoxides and thiobarbituric acid-
reactive substances (TBARS) which are also end-products of lipid peroxidation as well. In a study 
by Kikugawa et al., (2003) the effect of omega-3 fatty acid supplementation on oxidative stress- 
induced DNA damage of rat hepatocytes was studied using 32, four weeks old, male Wistar rats 
which were fed with 50g/kg dried diets consisting of either fish oil rich in EPA and DHA or 
safflower oil rich in omega-6 fatty acids and as well as equal amounts of vitamin E in 59g/kg of 
dried diet for 6 weeks5. The hepatocytes were isolated and exposed with in vitro hydrogen peroxide 
to induce oxidative stress and the lipid peroxidation level was measured with phospholipid 
hydroperoxides and thiobarbituric acid-reactive substances5. It was concluded that the level of 
lipid-peroxidation of hepatocytes increased slightly more in the omega-3 fatty acids group 
compared to the omega-6 fatty acids group5. Based on the above research, omega-3 fatty acids 
specifically EPA and DHA may produce higher levels of lipid peroxidation compared to omega-6 
fatty acids5. 
Another study looked at the effect of different ratios of dietary corn oil and fish oil and the 
influence of antioxidant addition on the growth and lipid peroxidation on MDA- MB231 mammary 
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tumor in athymic nude mice4. 164, four to five weeks old, female athymic nude mice were used in 
the study and were fed with varying levels of corn oil and fish oil at different ratios; one of the diet 
had antioxidants added into it4. The diets were fed for 6 to 8 weeks starting 7 to 10 days after the 
administration of human breast carcinoma MDA-MB2314.  TBARS were used to detect the level 
of lipid peroxidation and it was reported that the TBARS level in the human breast carcinomas 
increased in mice fed with fish oil diets without antioxidants4. That accumulation of TBAR levels 
reportedly helped to suppress tumor growth4. There was a direct relationship between the level of 
TBARS and level of fish oil fed4. The study showed positive effect of lipid peroxidation in 
mammary tumor as the growth of the tumor was suppressed.  
EPA and DHA have also been extensively studied for their effects on breast cancer7. Many 
studies were done in xenograft and transgenic mouse models and generally showed benefits of 
EPA and DHA7. Liu and Ma’s (2014) review mentioned breast cancer studies in chemically-
induced mice models supported omega-3 fatty acids’ anti-cancer effects7.  One of the studies 
mentioned in the review by Olivo and Hilakivi-Clarke (2005), compared the effects of varying 
levels of EPA and DHA and omega-6 fatty acids respectively on mammary tumorigenesis in rats11. 
The rats fed with a low omega-3 fatty acids diet showed elevated lipid peroxidation but lower 
incidence of mammary tumors when compared to mice-fed omega-6 fatty acids11. The review 
showed that EPA and DHA have mixed effects on mammary tumors. 
Chemotherapy, omega-3 fatty acids and lipid peroxidation in the liver  
 A study by Bhattacharya et al., (2013) looked at effect of dietary omega-3 and 
cyclophosphamide, a common chemotherapeutic agent, on lipid peroxidation in livers of 
autoimmune-prone NZB/W female mice2. Female NZB/W mice (n=40, two months old) were fed 
with either ad libitum or food restricted diets containing 5% corn oil or 5% fish oil supplemented 
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with equal levels of antioxidants2. Cyclophosphamide was used instead of doxorubicin but it is 
also an agent used to treat cancer13. The cyclophosphamide was injected every 10 days for 10 
months but the diet continued up until 12 months before being sacrificed2. The liver was analyzed 
for lipid peroxidation via TBARS and it was reported that omega-3 fatty acids with ad libitum 
dietary group exhibited more susceptibility to lipid peroxidation especially with the presence of 
cyclophosphamide than that of omega-6 fatty acids2.   
Omega-3 fatty acids and sucrose on lipid peroxidation in the liver  
 Ma et al., (2011) looked at sucrose-based high fat diet and sucrose’s effect on the anti-
inflammatory effect of fish oil in adipose tissue and obesity development in C57BL/6J male mice 
for 9 weeks8. The type of diets fed consisted of corn oil or fish oil supplemented with either protein 
or sucrose or a conventional low fat diet ad libitum8. It was reported that sucrose counteracted the 
anti-inflammatory effects of fish oil in adipose tissue8. However, sucrose did not reduce the ability 
of fish oil to prevent diet-induced accumulation of fat in the liver, which could decrease the amount 
of lipid peroxidation in the liver8. This study showed that omega-3 fatty acids may and may not be 
beneficial at limiting lipid peroxidation in the liver when sucrose is present. 
  The aim of this thesis project was to determine differences in lipid peroxidation, detected 
via 4-HNE, induced by diets of varying levels of sucrose and omega-3 fatty acids in 
ovariectomized, female mice after exposing them to mammary tumor or chemotherapy injections. 
This thesis focused on the liver as it is understudied in both mammary tumor and chemotherapy 
mice models. It is important to understand the liver and its function after exposure to mammary 
tumor and chemotherapy as it is the site responsible for metabolism of many commonly used 
anticancer agents4. 
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Materials and Methods 
Study design  
The analysis was performed on liver tissues from two different experiments which involved 
mouse models of mammary tumor and chemotherapy. Eight to nine week old, ovariectomized 
female (C57BL/6) mice were used for both mouse models. Figure 1 shows the timeline of the 
mammary tumor mouse model prior to laboratory analysis and Figure 2 shows the timeline of the 
chemotherapy mouse model prior to laboratory analysis.  
 
Figure 1: Timeline of the mammary tumor mouse model with the mice being ovariectomized on 
Day 0, fed with the different diets through pellet starting on Week 1 and continuing through end 
of study, tumor injection (E0771 metastatic mammary tumor cell line) on Week 2, and tissue 
collection, flash frozen with liquid nitrogen, and stored in freezer (-80ºC) on Week 3 
 
Figure 2: Timeline of the chemotherapy mouse model with the mice being ovariectomized on Day 
0, fed with the different diets through pellet starting on Week 1 and continuing through end of 
study, chemotherapy (50% Human Equivalent dose of 9mg/kg Doxorubicin and 90mg/kg 
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Cyclophosphamide) or saline injection on Week 3 and Week 5, and tissue collection, flash frozen 
with liquid nitrogen, and stored in freezer (-80ºC) on Week 6 
Mammary tumor mouse model 
Treatment  
The mice were injected with Dulbecco’s Modified Eagle Medium (DMEM) (Thermo 
Fisher, Waltham, MA), which was used as the control or with tumor cells (CH3 BioSystems, 
Amherst, NY). The tumor injected mice had E0771 metastatic mammary tumor cell line using 
intraperitoneal injections of 106 cells bilaterally.  
Diet 
An ingredient list consisting of the different mouse diets could be found in Appendix B. 
The total amount of omega-3 fatty acids used in the diets with 2% EPA+DHA was 23% (Appendix 
C). The ratio of omega-3 and omega-6 in the diets with 0% EPA +DHA was 1:7 while the ratio of 
omega-3 and omega-6 in the diets with 2% EPA+DHA was 1: 1.3 (Appendix C).  In the mammary 
tumor mouse model, two types of diet: low sucrose, 0% EPA + DHA and low sucrose, 2% EPA + 
DHA were used to feed the mice in the form of pellet. The compositions of the different diets are 
tabulated in Table 1. A total of 58 mice were used for both types of treatment but for 4-HNE 
analysis, 32 mice were randomly chosen with 8 per diet group. 
Table 1: Types of diet and their composition used in the mammary tumor mouse model 
Diet Sucrose (% kcal) Omega-3 fatty acids (% kcal) 
Low sucrose, 0% EPA+DHA 9 % kcal 0 % kcal 
Low sucrose, 2% EPA+DHA 9 % kcal 2 % kcal 
(EPA:DHA ratio = 1.5:1) 
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Chemotherapy mouse model  
Treatment 
The mice were injected with saline, which was used as the vehicle or with doxorubicin and 
cyclophosphamide via tail vein injections two weeks and four weeks after starting diets. The 
chemotherapy treated mice were injected with 50% Human Equivalent dose (9mg/kg Doxorubicin 
and 90mg/kg Cyclophosphamide) (Pfizer, New York City, New York; Baxter International, 
Deerfield, IL).  
Diet  
An ingredient list consisting of the different mouse diets could be found in Appendix B. 
The total amount of omega-3 fatty acids used in the diets with 2% EPA+DHA was 23% (Appendix 
C). The ratio of omega-3 and omega-6 in the diets with 0% EPA +DHA was 1:7 while the ratio of 
omega-3 and omega-6 in the diets with 2% EPA+DHA was 1: 1.3 (Appendix C). In the 
chemotherapy mouse model, four types of diet which were used: low sucrose, 2% EPA+DHA diet, 
low sucrose, 0% EPA+DHA diet, high sucrose, 2% EPA+DHA diet, and high sucrose, 0% 
EPA+DHA diet. The compositions of different diets are tabulated in Table 2. A total of 102 mice 
were used in the experiment but for 4-HNE analysis, liver samples from 40 mice were randomly 
chosen with 10 samples per diet group. 
Table 2: Types of diet and their composition used in the chemotherapy mouse model 
Diet Sucrose (% kcal) Omega-3 fatty acids (% 
kcal) 
Low sucrose, 2% EPA+DHA 9% kcal 2% kcal 
(EPA: DHA ratio = 1.5:1) 
Low sucrose, 0% EPA+DHA 9% kcal 0% kcal 
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High sucrose, 2% EPA+DHA 47% kcal 2% kcal 
(EPA: DHA ratio = 1.5:1) 
High sucrose, 0% EPA+DHA 45% kcal 0% kcal 
 
Laboratory Analysis 
Protein analysis 
Protein lysate from mouse liver samples were prepared by homogenizing with 1 X PBS 
with protease inhibitor cocktail, then centrifuged at 16100 rcf for 15 minutes at 4°C and collect 
supernatant. Next, Bicinchoninic Acid (BCA) Protein Assay (Fisher Scientific, Waltham, MA) 
was conducted to measure the protein in liver lysate.  Five microliter of protein lysates were added 
to 96-wells plate with 20 uL of lysis buffer (i.e., 1 X PBS with protease inhibitor cocktail) to dilute 
the sample. Then 200 uL working reagent (i.e., 50:1 of Reagent A and Reagent B) to each well. 
After 96-wells plate was incubated at 37 C for 30 minutes, absorbance was read with Synergy™ 
H1 hybrid microplate reader (Biotek, Winooski, VT) at 562 nm. The protein concentration was 
quantified regarding to a known concentration standard curve. The level of protein in samples was 
later used to normalize 4-HNE levels.  
HNE Protein Adduct 
 
The enzyme-linked immunoabsorbent assay (ELISA) kit (Cell Biolabs Inc., San Diego, 
CA) (Appendix A) was then used to analyze 4-HNE levels. The protein adducts were quantified 
through the comparison of the protein adducts’ absorbance with a known standard curve.  Firstly 
the HNE conjugate coated 96-wells plate was prepared by overnight incubation with 100 uL of 1X 
Conjugated Diluent containing 10 ug/mL HNE Conjugate at 4ºC on plate shaker.  
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The next day, the conjugate coated plate was washed twice with 200 uL of 1X PBS before 
use. Then 200 uL of assay diluent was pipetted into the 96-wells plate and incubated on plate 
shaker at room temperature. The HNE-BSA standard was prepared according to the kit manual 
while waiting for the plate incubation. After incubation, 50 uL of standard and samples were 
pipetted into the wells and then incubated for 10 minutes at room temperature on plate shaker.  
Next, 50 uL of diluted Anti-HNE antibody was pipetted into each well and left for 
incubation for an hour at room temperature on plate shaker. The primary antibody was used to 
detect specific HNE protein in samples. When the incubation period was done, the plate was 
washed 3 times with 250 uL of 1X wash buffer. The washing step was done to remove unbound 
reagents and help to increase the sensitivity of the ELISA kit. One hundred microliter of diluted 
Secondary Antibody-HRP Conjugate was added to the wells and incubate for hour room 
temperature on plate shaker. The washing step was repeated and 100 uL of substrate solution was 
added. The incubation period was 20 minutes at room temperature on plate shaker. The stop 
solution was added at 100 uL into each well after the incubation period. The HNE protein adduct 
absorbance was read with the spectrophotometer at 450 nm. The level of HNE protein adducts in 
samples is calculated by comparison with a known HNE-BSA standard curve. 
Statistical Analysis  
All statistical analysis was performed via JMP (SAS Institute Inc, Cary, NC). The student’s 
t-test was used to determine significant differences between the mean liver 4-HNE levels of 
different types of diet and the mean liver 4-HNE levels of the types of treatment in the two models. 
While the Tukey Kramer’s test assessed for interactions between for different treatments and 
different diets used in each mouse model. Results were considered statistically significant at a level 
of p < 0.05. 
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Results  
Mammary tumor mouse model  
Mean and standard error of mean are presented in Table 3. There were no statistically 
significant differences in mean 4-HNE by tumor or control group (Figure 3). Using two-way 
ANOVA analysis, we explored trends for differences by diet groups (Figure 4) and within diet and 
treatment groups (Figure 5). 
Table 3: Descriptive analysis of liver 4-HNE in mammary tumor mouse model  
Condition Variable Mean of 4-HNE ± 
standard error of mean 
(SEM) 
(ug HNE-BSA/ugProtein) 
Comparison of 
all treatments     
(Figure 3) 
Control 0.0649 ± 0.0066 
 
Tumor 0.0613 ± 0.0066 
 
Comparison of 
single diet to all 
treatments 
(Figure 4) 
2% kcal EPA+DHA 
diet 
Control 0.0564 ± 0.0079 
 
Tumor 0.0649 ± 0.0079 
 
0% kcal EPA+DHA 
diet 
Control 0.0656 ± 0.0108 
 
Tumor 0.0648 ± 0.0108 
 
Comparison of 
all diets 
(Figure 5) 
2% kcal EPA + DHA diet 0.0607 ± 0.0069 
 
0% kcal EPA + DHA diet 0.0652 ± 0.0064 
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Figure 3: Comparison of liver 4-HNE in tumor vs control mice, without respect to diet group. p 
value = 0.7091(2 sample t-test)  
 
 
 
Figure 4: Comparison of liver 4-HNE in tumor vs control mice by diet groups. p-value for 
differences between injection treatments in mice fed 2% kcal EPA+ DHA diet = 0.4597 (2-way 
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ANOVA) and p-value for differences between injection treatments in mice fed 0% kcal EPA + 
DHA diet = 0.9570 (2-way ANOVA)   
 
Figure 5: Comparison of liver 4-HNE by diet group without respect to injection treatment. p-value 
for differences between diet groups = 0.6345 (2-way ANOVA)  
Chemotherapy mouse model  
Mean (SEM) of 4-HNE values in the chemotherapy model mice are presented in Table 4. 
There were no statistically significant differences in mean 4-HNE by chemotherapy or control 
group (Figure 6). Using two-way ANOVA analysis, we explored trends for differences by diet 
groups (Figure 7), within diet and treatment groups (Figure 8).  
Table 4: Descriptive analysis of liver 4-HNE in chemotherapy mouse model 
Condition Variable Mean of 4-HNE ± SEM 
(ug HNE-
BSA/ugProtein) 
Comparison of 
all treatments, 
without respect 
to diet groups 
(Figure 6) 
 
Vehicle 0.0876 ± 0.0114 
 
Chemotherapy 0.0817 ± 0.0114 
 
Comparison of 
single diet to all 
treatments and 
comparison of 
Low sucrose, 2% kcal 
EPA + DHA diet 
Vehicle 0.1094 ± 0.0241 
 
Chemotherapy 0.0751 ± 0.0241 
 
Vehicle 0.0923 ± 0.0254 
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single treatment 
to all diets 
(Figure 7)  
Low sucrose, 0% kcal 
EPA + DHA diet 
 
Chemotherapy 0.0975 ± 0.0254 
 
High sucrose, 2% kcal 
EPA + DHA diet 
Vehicle 0.0873 ± 0.0280 
 
Chemotherapy 0.0908 ± 0.0280 
 
High sucrose, 0% kcal 
EPA + DHA diet 
Vehicle 0.0550 ± 0.0152 
 
Chemotherapy 0.0634 ± 0.1365 
 
Comparison of 
all diets without 
respect to 
treatments 
(Figure 9)  
Low sucrose 2% kcal EPA + 
DHA diet 
0.0922 ± 0.0160 
 
0% kcal EPA + 
DHA diet 
0.0949 ± 0.0160 
 
High sucrose 2% kcal EPA + 
DHA diet 
0.0890 ± 0.0160 
 
0% kcal EPA + 
DHA diet 
0.0596 ± 0.0169 
 
 
 
Figure 6: Comparison of liver 4-HNE in chemotherapy vs vehicle treated mice, without respect to 
diet group. p-value = 0.7199 (2 sample t-test)  
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Figure 7a – Comparison of liver 4-HNE of all diet groups in chemotherapy treated mice. p-value 
for differences between all diets = 0.7698  
Figure 7b – Comparison of liver 4-HNE of all diet groups in vehicle treated mice. p-value for 
differences between all diets = 0.4621 
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Figure 8 – Comparison of liver 4-HNE by diet group, without respect to treatment. p-value = 
0.4228 (2-way ANOVA)  
Discussion  
The findings in this study suggested that there were no statistically significant differences 
between injection treatment groups or, diet groups, in liver 4-HNE levels when mice were fed 
varying levels of sucrose and omega-3 fatty acids and subjected to mammary tumor or 
chemotherapy injections.  
Mammary tumor, omega-3 fatty acids and lipid peroxidation in the liver 
 The results from the mammary tumor model of this thesis differ from the studies conducted 
by Kikugawa et al., (2003), Gonzalez et al., (1993) and Olivo and Hilakivi-Clarke (2005). The 
studies showed that omega-3 fatty acids increased lipid peroxidation in mammary tumor in mice 
liver4,5,11. However, the thesis results showed no significant differences between omega-3 fatty 
acids and lipid peroxidation in mice liver.   
Chemotherapy, omega-3 fatty acids and lipid peroxidation in the liver  
 The comparison of the results from the chemotherapy model of this thesis to the studies 
conducted by Bhattacharya et al., (2013) are different. The study found that omega-3 fatty acids 
were more susceptible to lipid peroxidation with the presence of chemotherapy2 while this thesis 
found no differences in lipid peroxidation in liver.  
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Omega-3 fatty acids, sucrose and lipid peroxidation in the liver 
 The comparison of the results from the chemotherapy model of this thesis to the studies 
conducted by Ma et al., (2011) suggests different direction. The study suggested that sucrose might 
not have reduced omega-3 fatty acid’s ability to prevent diet-induced accumulation of fat in the 
liver, which could decrease the amount of lipid peroxidation in the liver8 while this thesis results 
were not significantly different.  
 The different results obtained in this thesis analysis compared to studies published might 
be because the mice were not exposed to as much chemotherapy treatment to produce the side-
effects of treatment which includes lipid peroxidation. Moreover, there might be certain 
compounds or substances in the diets itself that were protecting the cells from lipid peroxidation. 
α-linolenic acid (ALA) content in the 0% EPA and DHA diet was much higher (7% of kcal) than 
the Adequate Intake of ALA for 19 to 70-year-old women (1.1grams/day or approximately 0.5% 
of an 1800 kcal/d diet), which could have helped protect the cells. The Adequate Intake levels are 
based on average consumption of ALA. 4-HNE is also a down-stream product of arachidonic acid 
(AA) instead of omega-3 fatty acids like ALA, EPA and DHA hence different biomarker of lipid 
peroxidation for this thesis could be assessed. The sample size of the two mice models were small 
as well and that could have given a relatively weaker power to detect significant relationships 
between the data of the study. 
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Conclusion  
 In conclusion, we found that various levels of sucrose and omega-3 fatty acid dietary 
modification did not cause lipid peroxidation in the liver to significantly differ in mouse models 
of breast cancer and chemotherapy. In regards to the efficacy of omega-3 fatty acid in limiting 
lipid peroxidation in both mammary tumor and chemotherapy models, further analysis of the 
models with different lipid peroxidation biomarkers should be done. A comparison between a low 
ALA diet with high EPA and DHA diets could give a clearer picture of differences in lipid 
peroxidation effects. In the future, statistical analysis using a three-way ANOVA looking at 
sucrose, omega-3 fatty acids and treatments should be done to identify if sucrose or omega-3 fatty 
acids alone compared to treatments would produce significant differences. A longer time frame of 
feeding could be investigated as well as numerous injection treatments, more closely mirroring 
chemotherapy in humans. The role and benefits of omega-3 fatty acids in helping to prevent 
oxidative stress in the liver is important to understand in order to help alleviate side-effects of 
patients who are going through chemotherapy. Hence, continuation of research involving efficacy 
of omega-3 fatty acids as well as interactions with different anticancer agents and sucrose should 
be studied.  
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Appendix A 
The protocol manual was prepared by Dr. Panchita Phuwamongkolwiwat-Chu 
Protein Extraction 
 
1.   Label 2 sets of 2.5 mL Eppendorf tube each sample with different color markers (one set 
is used for homogenization and another one is for supernatant after centrifugation) 
a.   Keep Eppendorf tubes on ice 
 
2.   Prepare 1X PBS from 10XPBS by estimating 1000 uL per sample (as needed) 
 
3.   Dissolve 1 tablet of protease inhibitor (Roche cat# 11836153001) into10 mL of 1xPBS   
a.   Store on ice or in the fridge (once protease inhibitor added, the buffer is good for 
1 week at 4°C) 
 
4.   Cut about 50 mg of brain tissue (Note: 5 -10 mg of liver tissue) on dry ice and record 
weight (keep frozen at all times) 
 
5.   Add the brain sample to the appropriate homogenization Eppendorf tube 
6.   Add 10x (v/w) 1XPBS with protease to labeled Eppendorf tubes on ice (Note: 100x v/w 
for liver) 
a.   i.e. 50.6 mg (0.0506 g) of tissue = 506 uL of 1xPBS with protease 
Note: if the total volume is more than 1000 uL, first add 1000 uL for homogenization 
then add the rest volume after to prevent overflow during homogenization  
7.   Homogenize the sample using 5 mm homogenizer probe for 15-20 second at level 4 
 
8.   Immediately place Eppendorf tubes on ice and keep in ice till all samples finish 
 
9.   Wash the probe by running in plastic homogenization tubes containing 4 mL 1X PBS (1 
set contains 4 tubes for washing after every 5 samples) 
 
Repeat steps 4-9 for all samples 
 
10.  Once all samples are homogenized, incubate on the shaker in cold room for 1 hour 
 
11.  Centrifuge at 16100 rcf for 15 minutes at 4°C (cold room) 
 
 25 
12.  Use 200 or 1000 ul pipette to transfer supernatant (clear liquid on surface) to new 
Eppendorf tubes  
a.   Must store on ice after transfer 
 
13.  Continue to BCA Protein assay or store at -80°C freezer for later 
BCA Protein Assay (Pierce BCA Protein Assay Kit, Thermo Scientific Cat#23225) 
(Note: If samples are from -80°C freezer, let samples thaw on ice) 
 
1.   Make Standards in microcentrifuge tubes (can be use again; store at RT) 
Standard Concentration 
(ug/ml) 
BSA 
(ul) 
DI H2O 
(ul) 
0 0 0 300 
1 125 18.75 281.25 
2 250 37.5 262.5 
3 500 75 225 
4 750 112.5 187.5 
5 1000 150 150 
6 1500 225 75 
7 2000 300 0 
 
2.   Set up 96 well plate as follows 
 
 
3.   Make a working Reagent (~300ul per sample and standard) 
a.   Mixing 50 parts of Reagent A with 1 parts of Reagent B (50:1 Reagent A / 
Reagent B, v/v)  
Example: 96 wells x 250 uL = 24,000 uL = 24mL 
Prepare 25 mL working solution:  
 Reagent A = 25 mL: Reagent B = 0.5 mL (500 uL) 
 
4.   Add 25 uL of each standard/ to wells of 96 well plate (touch pipette tip to top of the 
wells) 
1 2 3 4 5 6 7 8 9 10 11 12
A std	  0 std	  0 1 1 9 9 17 17 25 25 33 33
B std	  1 std	  1 2 2 10 10 18 18 26 26 34 34
C std	  2 std	  2 3 3 11 11 19 19 27 27 35 35
D std	  3 std	  3 4 4 12 12 20 20 28 28 36 36
E std	  4 std	  4 5 5 13 13 21 21 29 29 37 37
F std	  5 std	  5 6 6 14 14 22 22 30 30 38 38
G std	  6 std	  6 7 7 15 15 23 23 31 31 39 39
H std	  7 std	  7 8 8 16 16 24 24 32 32 40 40
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** For brain sample: 5 uL of sample and 20 uL of 1 X PBS + Protease inhibitor buffer to each 
wells 
 
5.   Add 200 uL of Working Reagent to each well with multichannel pipette (touch pipette tip 
to left side of wells) 
 
6.   Place on shaker for about 10-15 seconds 
 
7.   Incubate @ 37°C for 30 minutes (incubator is at Room 362 D, please check with Dr. Julie 
C. before using) 
 
8.   Allow plate to cool to RT (~5 minutes) and check whether there is any bubble in the well 
or not. IF there is bubble, please use the clean pipet tip to blow air to remove the bubble. 
 
9.   Read absorbance at 562 nm (using BCA protocol in spectrometer program) 
 
10.  Continue to 4HNE ELISA or store samples in freezer in -80 for later 
OxiSelectTM HNE Adduct Competitive ELISA Kit (Cat# STA-838) 
 
DAY 1: Prepare HNE Conjugate Coated Plate: 
1)   Prepare 1X Conjugated Diluent from 100X Conjugated Diluent with 1X PBS 
(immediately before use) 
2)   Prepare 10 ug/ mL HNE Conjugate from 1.0 mg/ mL HNE Conjugate with 1X PBS 
(immediately before use) 
3)   Mix solution from step 1) and 2) to 1:1 ratio 
4)   Pipet 100 uL of the mixture of 1X Conjugated Diluent and 10 ug/ mL HNE Conjugate 
(step 3)) into each well 
5)   Cover the plate with Parafilm wrap and incubate overnight at 4°C in plate shaker (cold 
room) 
DAY 2:  Assay Protocol 
Note:  
•   If samples are from -80°C freezer, let samples thaw on ice 
•   Remove HNE-BSA from -20 freezer and thaw on ice 
 
1)   Remove the HNE Conjugate Coated plate (from Day 1) from cold room 
2)   Discard the solution in the plate at wash sink 
3)   Wash with 200 uL 1X PBS, blot plate on the clean paper towel to remove excess fluid 
4)   Repeat step 2) -3) again  
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5)   Pipet 200 uL of Assay diluent to each well and block for 1 hour on plate shaker in room 
temperature 
6)   While waiting, prepare 1X Wash buffer:  
a.   Dilute 10X Wash buffer to 1X with Deionized water 
Example: 96 wells * 250 uL/well * 3 times * 2 steps = 144,000 uL = 144 mL 
Prepare 150 mL 1X Wash buffer 
  C1V1  = C2V2 
 10 (x) = 1(150) 
 X = 1(150)/10 
  = 15 mL of 10X Wash buffer in 135 mL Deionized water  
b.   Swirl until homogeneity 
 
7)   Prepare label 2.5 mL Eppendorf tubes for HNE-BSA standards as below: 
 
Standard 1 mg/mL HNE-BSA 
standard (uL) 
Assay diluent 
(uL) 
HNE-BSA 
(ug/mL) 
Concentration 
1 80 320 200 
2 200 of tube 1 200 100 
3 200 of tube 2 200 50 
4 200 of tube 3 200 25 
5 200 of tube 4 200 12.5 
6 200 of tube 5 200 6.25 
7 200 of tube 6 200 3.13 
8 200 of tube 7 200 1.56 
9 0 200 0 
a.   Vortex thoroughly  
b.   Place on the ice at all time 
 
8)   Set of 96 well Plate as shown below 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A STD 
1 
STD 
9 
1 1 9 9 17 17 25 25 33 33 
B STD 
2 
STD 
2 
2 2 10 10 18 18 26 26 34 34 
C STD 
3 
STD 
3 
3 3 11 11 19 19 27 27 35 35 
D STD 
4 
STD 
4 
4 4 12 12 20 20 28 28 36 36 
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E STD 
5 
STD 
5 
5 5 13 13 21 21 29 29 37 37 
F STD 
6 
STD 
6 
6 6 14 14 22 22 30 30 38 38 
G STD 
7 
STD 
7 
7 7 15 15 23 23 31 31 39 39 
H STD 
8 
STD 
8 
8 8 16 16 24 24 32 32 40 40 
 
9)   Pipet 50 uL of standards to 96 well (touch pipette tip to top of well) 
10)  Pipet 50 uL sample (touch pipette tip to top of well) 
Note: before pipet standards/samples vortex thoroughly before 
11)  Incubate for 10 minutes at room temperature on plate shaker  
12)  While waiting, prepare the diluted Anti-HNE antibody: 
•   Dilute Anti-HNE antibody 1:1000 
Example: 96 wells * 50 uL/well = 4,800 uL ~ 5 mL 
Prepare 5 mL of Dilute Anti-HNE antibody 
  C1V1   = C2V2 
 1000 (x) = 1(5) 
 X  = 1(5)/1000 
   = 0.005 mL of 1000 X Anti-HNE antibody  
So, 5 uL of Anti-HNE to 4.995 mL of Assay Diluent 
 
13)  After incubation, pipet 50 uL of the diluted Anti-HNE antibody (step 12) to each well. 
14)  Incubate for 1 hour at room temperature on plate shaker 
15)  Once plate is through incubating, wash wells 3 times with 250 uL of 1X Wash Buffer 
using multichannel pipette  
 
16)  While waiting, prepare the diluted Anti-HNE antibody: 
•   Dilute Secondary Antibody 1:1000 
Example: 96 wells * 10 uL/well = 9,600 uL ~ 10 mL 
Prepare 10 mL of Dilute Anti-HNE antibody 
  C1V1   = C2V2 
 1000 (x) = 1(10) 
 X  = 1(10)/1000 
   = 0.01 mL of 1000 X Anti-HNE antibody  
So, 10 uL of Anti-HNE to 9.990 mL of Assay Diluent 
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17)  Pipet 100 uL of the diluted Secondary Antibody (step 16) in each well (touch pipette tip 
to right side of well) 
18)  Incubate for 1 hours at RT on orbital shaker   
(Note: While incubating; warm Substrate solution to room temperature) 
19)  Repeat washing step as step 15 above. 
20)  Pipet 100 uL of Substrate Solution to each well 
21)  Incubate for 20 minutes at room temperature on plate shaker 
Note: watch plate carefully; if color changes rapidly, the reaction may need to be 
stopped sooner to prevent saturation (I did 20 minutes) 
Note: turn on the plate reader and set the temperature at 37 °C 
22)  Add 100 uL of Stop Solution to each well (tough pipette tip to right side of well) 
23)  Read absorbance at 450 nm immediately 
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Appendix B  
 
Mouse Diet Formulations were prepared by Research Diets, Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0% 
EPA+DHA/ 
LOW 
SUCROSE 
0% 
EPA+DHA/ 
HIGH 
SUCROSE 
2% 
EPA+DHA/ 
LOW 
SUCROSE 
2% 
EPA+DHA/ 
HIGH 
SUCROSE 
Ingredient  gm/kg gm/kg gm/kg gm/kg 
Casein 232.5 232.5 205 205 
DL-Methionine 3 3 3 3 
Corn Starch 450  100 450 100 
Sucrose 100 500 100 500 
Maltodextrin10 100  50 100 50 
Cellulose 50 50 50 50 
Soybean Oil  90 90 41                  41  
MEG-3, 30% 
Powder 
0 0 81                81  
Mineral mix 35 35 35 35 
Vitamin mix 10 10 10 10 
Choline 2 2 2 2 
     
Protein (gm%) 19 19 19 19 
Carbohydrate 
(gm%) 
61 61 61 61 
Fat (gm%) 8 8 8 8 
          
Protein (kcal%) 19 19 19 19 
Carbohydrate 
(kcal%) 
61 61 61 61 
Fat (kcal%) 19 19 19 19 
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Appendix C 
 
Fatty acid composition of mouse diets prepared by Kate Ormiston from Dr. Orchard’s lab  
!
! Diets!
Dietary!
Fatty!Acid!
NO!EPA+DHA/!!
LOW!SUCROSE!
NO!EPA+DHA/!!
HIGH!SUCROSE!
2%!EPA+DHA/!!
LOW!SUCROSE!
2%!EPA+DHA/!
HIGH!SUCROSE!
!! Mean% % SD% Mean% % SD% Mean% % SD% Mean% % SD%
C14:0! 0.3127' 0.0056' 0.3465' 0.0183' 4.0342' 0.0655' 4.0396' 0.1155'
C16:0! 10.8571' 0.0044' 10.8156' 0.0162' 15.6643' 0.0515' 15.6578' 0.1455'
C16:1n7! 0.1246' 0.0102' 0.1256' 0.0121' 4.7284' 0.0682' 4.7533' 0.1353'
C16:2n4! ND' ' ND' ' 0.6467' 0.0136' 0.6746' 0.0129'
C16:3n4! 0.0585' 0.0033' 0.0580' 0.0018' 0.7979' 0.0132' 0.7923' 0.0207'
C18:0! 3.7595' 0.0075' 3.7911' 0.0128' 3.7329' 0.0262' 3.8003' 0.0131'
C18:1n9! 19.9944' 0.0661' 19.9874' 0.0771' 14.3479' 0.0526' 14.5019' 0.1299'
C18:1n7! 1.4386' 0.0437' 1.4651' 0.0507' 2.1407' 0.0437' 2.1796' 0.0354'
C18:2n6! 55.7595' 0.0116' 55.7239' 0.0613' 28.0789' 0.4165' 27.4273' 0.8709'
C18:3n6! ND' ' ND' ' 0.1622' 0.0088' 0.1744' 0.0152'
C18:3n3! 7.1302' 0.0301' 7.1640' 0.0585' 4.0564' 0.0457' 3.9617' 0.0978'
C18:4n3! ND' ' ND' ' 2.1081' 0.0256' 2.1021' 0.0458'
C20:0! 0.2380' 0.0153' 0.2492' 0.0068' 0.4335' 0.0129' 0.4489' 0.0220'
C20:1n9! 0.1587' 0.0057' 0.1676' 0.0039' 0.8631' 0.0403' 0.9112' 0.0393'
C20:2n6! 0.0424' 0.0044' ND' ' 0.1139' 0.0040' 0.1141' 0.0067'
C20:3n6! ND' ' ND' ' 0.0954' 0.0057' 0.0990' 0.0071'
C20:4n6! ND' ' ND' ' 0.4834' 0.0083' 0.4938' 0.0109'
C20:4n3! ND' ' ND' ' 0.5428' 0.0136' 0.5548' 0.0225'
C20:5n3! ND' ' ND' ' 9.2107' 0.1225' 9.3503' 0.2936'
C22:4n6! 0.0989' 0.0152' 0.0988' 0.0067' 0.1218' 0.0623' 0.1128' 0.0966'
C22:5n6! ND' ' ND' ' 0.1417' 0.0131' 0.1481' 0.0094'
C22:5n3! 0.0740' 0.0256' 0.0602' 0.0035' 0.8908' 0.0689' 0.9321' 0.1051'
C22:6n3! ND' ' ND' ' 6.6043' 0.1001' 6.7700' 0.2156'
Total!nM3! 7.2042' 0.0501' 7.2041' 0.0238' 23.4131' 0.3142' 23.6710' 0.5725'
Total!nM6! 55.8537' 0.0765' 55.7897' 0.0145' 29.1974' 0.4603' 28.5695' 0.9279'
nM3/nM6! 0.1290' 0.0011' 0.1291' 0.0004' 0.8021' 0.0231' 0.8296' 0.0470'
nM6/nM3! 7.7533' 0.0642' 7.7442' 0.0254' 1.2474' 0.0364' 1.2080' 0.0685'
 
